Archive · 12 Aug 2025
Indian Pharma Companies Ready to Launch Cheaper Weight Loss Drugs
Big pharmaceutical companies in India are getting ready to make cheaper versions of a popular medicine called semaglutide.
This medicine helps people with diabetes and those trying to lose weight.
Right now, it's very expensive, costing up to Rs 26,000 a month.
The new versions should be much cheaper, making them available to more people.
Companies like Dr Reddy's and Cipla are investing a lot to make these drugs.
There are some concerns about how these weight loss drugs are being used, and a government group is looking into it.
The companies are working hard to get their versions out soon to help more people and take part in the growing market.
Indian pharma companies are preparing to launch generic versions of semaglutide, a drug used for diabetes and weight loss.
Generic versions aim to significantly reduce the current monthly cost of Rs 17,000-Rs 26,000 for consumers.
Dr Reddy's, Cipla, Sun Pharma, and Mankind Pharma are among the companies planning launches.
The Central Drugs Standard Control Organisation (CDSCO) is forming a panel to address concerns over unregulated weight-loss drug use.
India's peptide CDMO market, estimated at $80 million, is experiencing growth.
- Who
- Dr Reddy's, Cipla, Sun Pharma, and Mankind Pharma
- What
- Indian pharma companies are preparing to launch generic versions of semaglutide, a drug used for diabetes and weight loss.
- When
- Generic versions are expected to launch around March next year after the patent expires.
- Where
- India
- Why
- To provide more affordable access to weight-loss and diabetes treatments.
Concerns over Unregulated Use
Increased Accessibility and Affordability
Safety Data
Concerns over Unregulated Use
Concerns arise from approvals for weight management drugs like semaglutide, tirzepatide, and liraglutide, due to limited safety data and absence of India-specific clinical trials.
Increased Accessibility and Affordability
N/A
- Drug Name
- Semaglutide
- Current Monthly Cost
- Rs 17,000-Rs 26,000
- Targeted Market
- Weight Loss, Type-II Diabetes
- Companies Involved
- Dr Reddy's, Cipla, Sun Pharma, Mankind Pharma
- Market Size (Global)
- Estimated to cross $150 billion by the end of the decade
- CDMO Market Size (India)
- $80 million